Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Plasma cell 1

Conditions

Neoplasms 2Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Crizotinib × Clear all
NCT02473497 2024-06-26

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Pfizer

No longer available
Tumor-Agnostic

Neoplasms

NCT03085186 2017-08-29

Treatment With Crizotinib Single Patient Expanded Access IND 134375

University of Pittsburgh

No longer available
Plasma cell

Granuloma, Plasma Cell

NCT02824094 2017-07-21

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Pfizer

No longer available
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡